title: p300 Influences Butyrate-Mediated WNT Hyperactivation In Colorectal Cancer Cells.
abstract: Deregulated WNT/catenin pathway, usually resulting from mutations in the adenomatous polyposis coli and beta-catenin genes, drives colorectal tumorigenesis. Dietary fiber has been shown to have a protective role against colorectal cancer (CRC). We have previously demonstrated that the histone deacetylase inhibitor (HDACi) butyrate, a fermentation product of dietary fiber, induces WNT/catenin hyperactivation, which promotes CRC cell apoptosis. Therefore, the ability of butyrate to induce WNT hyperactivation and thus promote CRC cell apoptosis may in part explain the preventive function of fiber against CRC. The association between beta-catenin and the transcriptional coactivator p300 may influence WNT/catenin signaling and, therefore, colonic cell physiology. p300 functions as a histone acetylase (HAT); therefore, the modulation of WNT/catenin activity by p300 may influence the ability of the HDACi butyrate to hyperinduce WNT signaling and apoptosis in CRC cells. Our findings indicate that p300 affects the hyperinduction of WNT activity by butyrate. Knockdown of p300 levels represses butyrate-mediated WNT/catenin activity; but still allows for butyrate-mediated apoptosis. Overexpression of p300 stimulates basal and butyrate-induced WNT signaling in some, but not all, CRC cell lines. We also evaluate the role of p300 in therapeutic approaches that target CBP. The small molecule ICG-001, in clinical trial, is a specific inhibitor of CBP-mediated WNT signaling, and previous studies have suggested that p300 is required for the activity of ICG-001. However, we report that ICG-001 maintains full activity against CBP-mediated WNT signaling in p300-deficient cell lines, including the butyrate-resistance line HCT-R. In addition, our findings evaluating combinatorial treatment of ICG-001 and butyrate in HCT-R cells may have important therapeutic implications for the treatment of butyrate-resistant CRCs.
authors.affiliation: Department of Basic Sciences, The Commonwealth Medical College, 525 Pine Street, Scranton, PA 18509, USA.
authors.forename: Darina L
authors.initials: DL
authors.lastname: Lazarova
authors.forename: Terrence
authors.initials: T
authors.lastname: Wong
authors.forename: Christopher
authors.initials: C
authors.lastname: Chiaro
authors.forename: Eric
authors.initials: E
authors.lastname: Drago
authors.forename: Michael
authors.initials: M
authors.lastname: Bordonaro
keywords: ICG-001.; WNT; butyrate; colorectal cancer; fiber; p300
references.citation: Lancet. 2003 May 3;361(9368):1491-5
references.pmid: 12737857
references.citation: Exp Cell Res. 2007 May 1;313(8):1652-66
references.pmid: 17359971
references.citation: Proc Natl Acad Sci U S A. 2004 May 11;101(19):7386-91
references.pmid: 15123817
references.citation: Nature. 1998 Oct 1;395(6701):521-5
references.pmid: 9774110
references.citation: Adv Drug Deliv Rev. 2010 Sep 30;62(12):1149-55
references.pmid: 20920541
references.citation: Eur J Cancer. 2002 Sep;38(14):1937-45
references.pmid: 12204677
references.citation: Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5668-73
references.pmid: 17372190
references.citation: Mol Cell Biol. 2004 Apr;24(8):3404-14
references.pmid: 15060161
references.citation: Cell. 2000 Oct 13;103(2):311-20
references.pmid: 11057903
references.citation: Cancer Res. 1992 Nov 1;52(21):5906-12
references.pmid: 1327519
references.citation: Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12171-6
references.pmid: 16093313
references.citation: Med Res Rev. 2006 Jul;26(4):397-413
references.pmid: 16450343
references.citation: Int J Cancer. 2004 Jul 1;110(4):523-31
references.pmid: 15122584
references.citation: Cancer Res. 1994 Jun 15;54(12):3288-93
references.pmid: 8205551
references.citation: Science. 1997 Mar 21;275(5307):1787-90
references.pmid: 9065402
references.citation: J Cancer Res Clin Oncol. 2005 Oct;131(10):692-700
references.pmid: 16133571
references.citation: Lancet. 2003 May 3;361(9368):1496-501
references.pmid: 12737858
references.citation: Int J Cancer. 1995 Jan 27;60(3):400-6
references.pmid: 7829251
references.citation: Expert Opin Investig Drugs. 2005 Dec;14(12):1497-511
references.pmid: 16307490
references.citation: Oncogene. 2005 May 19;24(22):3619-31
references.pmid: 15782138
references.citation: Oncogene. 2004 Jan 22;23(3):639-45
references.pmid: 14737099
references.citation: Cancer Res. 1997 Sep 1;57(17):3697-707
references.pmid: 9288776
references.citation: Clin Cancer Res. 2010 Jun 15;16(12):3153-62
references.pmid: 20530697
references.citation: J Cancer. 2013 Jul 15;4(6):481-90
references.pmid: 23901348
references.citation: EMBO J. 2007 May 2;26(9):2284-94
references.pmid: 17410209
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1552-6
references.pmid: 15941971
references.citation: Biochem Biophys Res Commun. 2012 Nov 9;428(1):121-6
references.pmid: 23063976
references.citation: Proc Nutr Soc. 1990 Jul;49(2):153-71
references.pmid: 2172992
references.citation: Nat Rev Cancer. 2005 Sep;5(9):744-9
references.pmid: 16148886
references.citation: Hum Mol Genet. 2002 Jun 15;11(13):1549-60
references.pmid: 12045208
references.citation: Gut. 1987 Oct;28(10):1221-7
references.pmid: 3678950
references.citation: Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12682-7
references.pmid: 15314234
references.citation: EMBO J. 2000 Apr 17;19(8):1839-50
references.pmid: 10775268
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1273-8
references.pmid: 14732695
references.citation: Drug Discov Today. 2005 Nov 1;10(21):1467-74
references.pmid: 16243267
references.citation: Oncol Res. 2008;17(1):1-9
references.pmid: 18488710
references.citation: Science. 1997 Mar 21;275(5307):1784-7
references.pmid: 9065401
references.citation: Cell Growth Differ. 1999 Oct;10(10):713-20
references.pmid: 10547075